Post-therapeutic surveillance of HPV-driven oropharyngeal cancers: are we ready to change our practices?
HPV circulating DNA
Head neck cancer/neoplasm
Human papillomavirus (HPV)
Oropharynx/oropharyngeal
Post-therapeutic surveillance
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
01
01
2023
accepted:
28
03
2023
medline:
3
7
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
Although HPV-positive and negative oropharyngeal cancers are two distinct diseases, Post-Therapeutic Surveillance (PTS) modalities are similar. Adjusting PTS strategies to HPV status will represent a massive practice change that raises the issue of its acceptability, by both physicians and patients. Two distinct surveys were designed and submitted, respectively, to HPV-positive patients and physicians (surgeons, radiation and medical oncologists) involved in head and neck cancer treatment. 133 patients and 90 physicians have participated to the study. Most patients were reluctant to embrace new PTS options (remote consultations, nurse consultations and smart phone applications). However, 84% of patients would be favorable to use HPV Circulating DNA (HPV Ct DNA) measurement to guide surveillance modalities. 57% of physicians acknowledged that our current PTS strategy is improvable and most of them would accept the use of new monitoring options from the third year of follow-up. 87% of physicians would be interested to participate to a trial comparing the current PTS strategy to a new approach, where monitoring modalities (number of visits, imaging prescription) would depend on HPV Ct DNA level. Patients and physicians are aware that PTS modalities should depend on HPV status. Their adhesion is a prerequisite to any potential changes. Strategies based on HPV Ct DNA measurement should be assessed within a randomized clinical trial.
Identifiants
pubmed: 37010600
doi: 10.1007/s00405-023-07952-8
pii: 10.1007/s00405-023-07952-8
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3811-3820Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35
doi: 10.1056/NEJMoa0912217
pubmed: 20530316
pmcid: 2943767
Fakhry C, Westra WH, Li S. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma
www.sforl.org (French PTS recommendations)
www.nccn.org (American PTS recommendations)
Lee JY, Garcia-Murillas I, Cutts RJ et al (2017) Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Br J Cancer 117(6):876–883. https://doi.org/10.1038/bjc.2017.258
doi: 10.1038/bjc.2017.258
pubmed: 28809864
pmcid: 5589999
Chera BS, Kumar S, Beaty BT et al (2019) Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clin Cancer Res 25(15):4682–4690
doi: 10.1158/1078-0432.CCR-19-0211
pubmed: 31088830
pmcid: 6679766
Routman D, Chera BS, Jethwa K et al (2019) Detectable HPV ctDNA in Post-Operative oropharyngeal squamous cell carcinoma is associated with progression. Int J Radiat Oncol Biol Phys 105(3):682–683
doi: 10.1016/j.ijrobp.2019.08.033
Chera BS, Kumar S, Shen C et al (2020) Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol 38(10):1050–1058
doi: 10.1200/JCO.19.02444
pubmed: 32017652
pmcid: 7106982
- Reder H, Taferner VF, Wittekindt C, et al. Plasma cell-free human papillomavirus oncogene E6- and E7-DNA predicts outcome in oropharyngeal squamous cell carcinoma [published online ahead of print, 2020 Aug 18]. J Mol Diagn. 2020;S1525–1578(20)30429–3.
Ilmarinen T, Keski-Säntti H, Markkanen-Leppänen M et al (2019) De-escalation of post-treatment surveillance in oropharyngeal cancer. Head Neck 41(5):1457–1462
doi: 10.1002/hed.25593
pubmed: 30582249
Pagh A, Vedtofte T, Lynggaard CD et al (2013) The value of routine follow-up after treatment for head and neck cancer. A national survey from DAHANCA. Acta Oncol 52(2):277–284. https://doi.org/10.3109/0284186X.2012.741324
doi: 10.3109/0284186X.2012.741324
pubmed: 23320772
Schwartz DL, Barker J Jr, Chansky K et al (2003) Postradiotherapy surveillance practice for head and neck squamous cell carcinoma–too much for too little? Head Neck 25(12):990–999
doi: 10.1002/hed.10314
pubmed: 14648857
Malik A, Nair S, Sonawane K et al (2020) Outcomes of a telephone-based questionnaire for follow-up of patients who have completed curative-intent treatment for oral cancers. JAMA Otolaryngol Head Neck Surg 146(12):1102–1108. https://doi.org/10.1001/jamaoto.2020.2404
doi: 10.1001/jamaoto.2020.2404
pubmed: 32880626
Gharzai LA, Burger N, Li P, Jaworski EM et al (2021) Patient burden with current surveillance paradigm and factors associated with interest in altered surveillance for early stage HPV-related oropharyngeal cancer. Oncologist 26(8):676–684. https://doi.org/10.1002/onco.13784
doi: 10.1002/onco.13784
pubmed: 33823077
pmcid: 8342565
Frakes JM, Naghavi AO, Demetriou SK et al (2016) Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer 122(4):634–641
doi: 10.1002/cncr.29782
pubmed: 26565997
Masroor F, Corpman D, Carpenter DM, Ritterman Weintraub M, Cheung KHN, Wang KH (2019) Association of NCCN-recommended posttreatment surveillance with outcomes in patients with HPV-associated oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 145(10):903–908
doi: 10.1001/jamaoto.2019.1934
pubmed: 31393552
pmcid: 6692675
Chen MM, Mott NM, Miller J et al (2022) Clinician attitudes and beliefs about deintensifying head and neck cancer surveillance. JAMA Otolaryngol Head Neck Surg 148(1):43–51. https://doi.org/10.1001/jamaoto.2021.2824
doi: 10.1001/jamaoto.2021.2824
pubmed: 34734995
www.clinicaltrial.gov